Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279934 | 1.00 | MAOA (0.32) | MAOAMAOBLMNATSHR | |
| SCHEMBL10938530 | 0.84 | MAPT (0.33) | MAOAMAOB | |
| SCHEMBL10937868 | 0.83 | MAPT (0.33) | MAOAMAOB | |
| SCHEMBL10935590 | 0.83 | MAPT (0.33) | MAOAMAOB | |
| SCHEMBL4865141 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL4560700 | 0.75 | — | — | |
| SCHEMBL5744965 | 0.73 | — | — | |
| SCHEMBL30130599 | 0.72 | LMNA (0.30) | LMNATSHR | |
| SCHEMBL20969186 | 0.70 | — | — | |
| SCHEMBL15661939 | 0.69 | MAPT (0.34) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220142-A1 | ACTIVE-ENERGY-RAY-CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF | NIPPON SHOKUBAI CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| EP-1608668-B1 | TERTIARY PHOSPHINES AND THEIR METHODS OF PREPARATION | CYTEC CANADA INC (CA) | 2018-02-28 | — | — | EP | disclosed |
| US-7608713-B2 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | CYTEC CANADA INC. (CA) | 2009-10-27 | — | — | US | disclosed |
| US-7608713-B2 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | CYTEC CANADA INC. (CA) | 2009-10-27 | — | — | US | disclosed |
| US-20070037981-A1 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | CYTEC CANADA INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| US-20070037981-A1 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | CYTEC CANADA INC. (CA) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037981-A1 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | PHOSPHO1, PLCD1, PLCB3 | MAOA 4379/4885MAOB 4488/4885LMNA 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.